1051899-49-0

Basic information

• Product Name: 1-Piperazinecarboxylic acid, 4-[3-amino-5-(4-morpholinyl)phenyl]-, 1,1-dimethylethyl ester
• CAS NO: 1051899-49-0
• Molecular Formula: C19H30N4O3
• Molecular Weight: 362.472
• Mol File: 1051899-49-0.mol

Chemical Properties

• CAS DataBase Reference: 1-Piperazinecarboxylic acid, 4-[3-amino-5-(4-morpholinyl)phenyl]-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Piperazinecarboxylic acid, 4-[3-amino-5-(4-morpholinyl)phenyl]-, 1,1-dimethylethyl ester(1051899-49-0)
• EPA Substance Registry System: 1-Piperazinecarboxylic acid, 4-[3-amino-5-(4-morpholinyl)phenyl]-, 1,1-dimethylethyl ester(1051899-49-0)

Safety Data

• Hazardous Substances Data: 1051899-49-0(Hazardous Substances Data)

Usage

Functional groups

Piperazine, carboxylic acid, amino, phenyl, morpholinyl, ester

Classification

Tertiary amine, ester

Biological activities

Antitumor, anti-inflammatory, analgesic

Potential applications

Therapeutic agent for various diseases, scaffold for new drug molecules, organic synthesis, medicinal chemistry research

Note

The specific content and properties of 1-Piperazinecarboxylic acid, 4-[3-amino-5-(4-morpholinyl)phenyl]-, 1,1-dimethylethyl ester may vary based on the context and application. The information provided is a general summary of its properties and potential uses.

Upstream product

• 3819-88-3 1-fluoro-3-iodo-5-nitrobenzene 
• 1051899-19-4 4-(3-iodo-5-nitrophenyl)-morpholine 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 1051899-47-8 tert-butyl 4-(3-morpholino-5-nitrophenyl)piperazine-1-carboxylate 

Downstream Products

• 1051899-50-3 tert-butyl 4-(3-(4-((5-methoxy-2-methylphenyl)(methyl)amino)pyrimidin-2-ylamino)-5-morpholinophenyl)piperazine-1-carboxylate 
• 1051897-37-0 N₄-(5-methoxy-2-methylphenyl)-N₄-methyl-N₂-(3-morpholino-5-(piperazin-1-yl)phenyl)pyrimidine-2,4-diamine 

Relevant articles and documents

Preparation of a novel radiotracer targeting the EphB4 receptor via radiofluorination using spiro azetidinium salts as precursor

The visualization of Eph receptors, which are overexpressed in various tumor entities, using selective small molecule Eph inhibitors by means of positron emission tomography is a promising approach for tumor imaging. N-(Pyrimidinyl)indazolamines represent a class of compounds, which are known to have high affinity especially for the EphB4 receptor. Radiofluorination of these compounds could provide a highly specific imaging agent and was investigated using a classical nucleophilic introduction of [18F]fluoride as well as a less common nucleophilic ring-opening reaction of azetidinium salts. In the past, radiofluorinations using azetidinium precursors were demonstrated to result in high radiochemical yields in short periods. For this purpose, an azetidinium precursor based on the N-(pyrimidinyl)indazolamine lead compound was developed, and radiofluorination was successfully accomplished. The respective [18F]radiotracer was quickly prepared with high radiochemical purity >97% and in a radiochemical yield of 34%.

NOVEL PYRIMIDINE DERIVATIVES 698

The invention concerns compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R1, n, R2, R3, and R4 are as defined in the description. The present invention also relates to processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours or other proliferative conditions which are sensitive to the inhibition of EphB4 kinases.